Tonix Pharmaceuticals Holding (TNXP) Income from Continuing Operations (2011 - 2026)
Tonix Pharmaceuticals Holding (TNXP) posted quarterly Income from Continuing Operations of 40335000.0 for Q1 2026, down 155.66% year-over-year from 72470708.92 in Q1 2025, and up 14.07% quarter-over-quarter from 46942000.0 in Q4 2025.
Tonix Pharmaceuticals Holding (TNXP) Income from Continuing Operations (2011 - 2026) Analysis & Trends
Tonix Pharmaceuticals Holding's Income from Continuing Operations history runs 16 years deep, the most recent figure standing at 40335000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 155.66% year-over-year to 40335000.0; the TTM figure through Mar 2026 stood at 147486000.0 (down 9.97% YoY), while the FY2025 annual figure was 127666000.0, up 36.02% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 40335000.0, up from 46942000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 15777000.0 in Q1 2025, with the low at 78888000.0 in Q2 2024.
- The 5-year median for Income from Continuing Operations is 29140000.0 (2022), against an average of 31428352.94.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations sank 170.68% in 2024, then surged 64.08% in 2025.
- Tonix Pharmaceuticals Holding's Income from Continuing Operations stood at 31831000.0 in 2022, then rose by 17.26% to 26337000.0 in 2023, then advanced by 14.38% to 22549000.0 in 2024, then slumped by 108.18% to 46942000.0 in 2025, then rose by 14.07% to 40335000.0 in 2026.
- Business Quant data shows TNXP's Income from Continuing Operations at 40335000.0 in Q1 2026, 46942000.0 in Q4 2025, and 31871000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Tonix Pharmaceuticals Holding | 213.43 Mn | 213.43 Mn | 12.84 Mn | -43.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -43.93 Mn |
| Mar 31, 2026 | -40.34 Mn |
| Dec 31, 2025 | -46.94 Mn |
| Sep 30, 2025 | -31.87 Mn |
| Jun 30, 2025 | -28.34 Mn |
| Mar 31, 2025 | -15.78 Mn |
| Dec 31, 2024 | -22.55 Mn |
| Sep 30, 2024 | -16.90 Mn |
| Jun 30, 2024 | -78.89 Mn |
| Mar 31, 2024 | -23.14 Mn |
| Dec 31, 2023 | -26.34 Mn |
| Sep 30, 2023 | -29.23 Mn |
| Jun 30, 2023 | -29.14 Mn |
| Mar 31, 2023 | -33.14 Mn |
| Dec 31, 2022 | -31.83 Mn |
| Sep 30, 2022 | -29.14 Mn |
| Jun 30, 2022 | -24.15 Mn |
| Mar 31, 2022 | -26.57 Mn |
| Dec 31, 2021 | -29.71 Mn |
| Sep 30, 2021 | -18.67 Mn |